The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.

被引：0
|
作者：
O'Brien, N. A.
Browne, B. C.
Chow, L.
Ginther, C.
Bensadigh, B.
Arboleda, J.
Duffy, M. J.
Crown, J.
O'Donovan, N.
Slamon, D. J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Dublin City Univ, Dublin 9, Ireland
[3] St Vincents Univ Hosp, Dublin 4, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160S / 160S
页数：1
相关论文
共 50 条
  • [1] Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy
    O'Brien, Neil
    Browne, Brigid
    Chow, Lucy
    Ginther, Charles
    Bensadigh, Brian
    Atefi, Mohammad
    Arboleda, Jane
    Duffy, Michael
    Crown, John
    O'Donovan, Norma
    Slamon, Dennis
    CANCER RESEARCH, 2009, 69
  • [2] The Role of the PI3K/AKT, RAS/MAPK and Novel Signaling Pathways in Resistance to HER2-Targeted Therapy
    O'Brien, N. A.
    Wilcox, K.
    McDermott, M.
    Crown, J.
    O'Donovan, N.
    Slamon, D. J.
    CANCER RESEARCH, 2010, 70
  • [3] HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
    Neil Spector
    Wenle Xia
    Iman El-Hariry
    Yossi Yarden
    Sarah Bacus
    Breast Cancer Research, 9
  • [4] PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer
    Kim, Hyo Song
    Zhang, Xianglan
    Park, Kyu Hyun
    Park, Ji Soo
    Kim, Ki Hyang
    Chung, Hyun Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Jiang, Wei
    Ji, Meiju
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 3 - 22
  • [6] MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling
    Han, Ying
    Peng, Yinghui
    Fu, Yaojie
    Cai, Changjing
    Guo, Cao
    Liu, Shanshan
    Li, Yiyi
    Chen, Yihong
    Shen, Edward
    Long, Kexin
    Wang, Xinwen
    Yu, Jian
    Shen, Hong
    Zeng, Shan
    ADVANCED SCIENCE, 2020, 7 (13)
  • [7] Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition
    Goltsov, Alexey
    Faratian, Dana
    Langdon, Simon P.
    Bown, James
    Goryanin, Igor
    Harrison, David J.
    CELLULAR SIGNALLING, 2011, 23 (02) : 407 - 416
  • [8] Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
    O'Brien, Neil A.
    McDonald, Karen
    Tong, Luo
    von Euw, Erika
    Kalous, Ondrej
    Conklin, Dylan
    Hurvitz, Sara A.
    di Tomaso, Emmanuelle
    Schnell, Christian
    Linnartz, Ronald
    Finn, Richard S.
    Hirawat, Samit
    Slamon, Dennis J.
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3507 - 3520
  • [9] Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
    Stratikopoulos, Elias E.
    Dendy, Meaghan
    Szabolcs, Matthias
    Khaykin, Alan J.
    Lefebvre, Celine
    Zhou, Ming-Ming
    Parsons, Ramon
    CANCER CELL, 2015, 27 (06) : 837 - 851
  • [10] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
12345